Monopar Therapeutics Unveils Study Results on Wilson Disease
WILMETTE, Ill. - Monopar Therapeutics Inc. (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, recently presented compelling new data from their Phase 2 ALXN1840-WD-204 study at a prominent liver disease conference taking place between November 7-11, 2025. This event marked a significant opportunity for Monopar to share advancements in treating Wilson disease, a genetic disorder that leads to excessive copper accumulation in the body.
Exciting Presentation on Tiomolybdate Choline
Professor Aftab Ala, an esteemed hepatologist from King's College Hospital, delivered an oral presentation titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline.” This presentation detailed groundbreaking findings related to the effects of ALXN1840, also known as tiomolybdate choline, on copper regulation in patients.
Key Findings from the Research
The results revealed that patients treated with ALXN1840 showed a marked improvement in their copper balance. These changes were primarily due to increased fecal copper excretion, indicating that the drug effectively facilitates excess copper removal from the body. Statistically significant reductions in mean daily copper balance were noted, suggesting the treatment's efficacy over both the initial dosing phase and the complete treatment period.
Study Design and Treatment Regimen
The research involved a small cohort of patients, totaling eight participants, who either received 15 mg doses daily or every other day, and some even received a higher dosage of 30 mg daily. Throughout the treatment period of 39 days, data demonstrated consistent improvements in daily copper metabolism, leading to a promising outlook for improving the quality of life for those affected.
Further Insights and Data Presentation
In addition to the oral presentation, Monopar plans to share further clinical and nonclinical data that supports these findings at the conference, aiming to enhance understanding of the ALXN1840-WD-204 study implications.
About Monopar Therapeutics Inc.
Monopar is dedicated to addressing unmet medical needs through innovative therapies. Their portfolio includes ALXN1840 for Wilson disease, alongside a variety of advanced radiopharmaceutical programs targeting cancer treatment. Their commitment to research continues to thrive, showcasing promising developments like MNPR-101-Zr for advanced cancer imaging and therapeutic agents in different stages of clinical trials.
Continued Commitment to Advancement
Monopar Therapeutics remains focused on finding impactful solutions for conditions that currently lack effective treatments. As they present their new data, the company's leadership underscores the importance of innovative solutions, hoping to reshape the therapeutic landscape for patients suffering from complex diseases.
Frequently Asked Questions
What is Wilson Disease?
Wilson disease is a genetic disorder that leads to excessive copper accumulation in the body, which can cause severe liver and neurological complications.
What is ALXN1840?
ALXN1840, also known as tiomolybdate choline, is an innovative treatment for managing copper balance in Wilson disease patients.
How was the study conducted?
The study involved a small group of patients treated with different doses of ALXN1840 over an extended period, assessing the impact on copper excretion.
Where can I find more information about Monopar?
More details and updates about Monopar and their research can be found on their official website.
What are the next steps for Monopar?
Monopar plans to continue research and development efforts, sharing further data at conferences to support their findings and promote advancements in treatment options.
